{"database": "openregs", "table": "documents", "is_view": false, "human_description_en": "where docket_id = \"FDA-2013-D-0576\" sorted by posted_date descending", "rows": [["FDA-2013-D-0576-0019", "FDA", "FDA-2013-D-0576", "Considerations for the Design of Early-Phase Clinical Trials of Cellular and\nGene Therapy Products; Guidance for Industry", "Other", "Guidance", "2015-06-27T04:00:00Z", 2015, 6, "2015-06-27T04:00:00Z", null, "2024-11-11T20:58:54Z", null, 1, 0, "0900006481b2cd22"], ["FDA-2013-D-0576-0026", "FDA", "FDA-2013-D-0576", "Reference 6 Donor-Derived Brain Tumor Following Neural Stem Cell Transplantation in an Ataxia Telangiectasia Patient re Considerations for the Design of Early-Phase Clinical Trials of Cellular and Gene Therapy Products; Guidance for Industry", "Supporting & Related Material", "Background Material", "2015-06-11T04:00:00Z", 2015, 6, null, null, "2015-06-11T14:25:50Z", null, 0, 0, "0900006481b2cdca"], ["FDA-2013-D-0576-0030", "FDA", "FDA-2013-D-0576", "Reference 10 Additional Safeguards for Children in Clinical Investigations of Food and Drug Administration_Regulated Products 78FedReg12937 2-26-13 re Considerations for the Design of Early-Phase Clinical Trials of Cellular and Gene Therapy Products; Guidance for Industry", "Supporting & Related Material", "Background Material", "2015-06-11T04:00:00Z", 2015, 6, null, null, "2015-06-11T14:26:55Z", null, 0, 0, "0900006481b2c9dd"], ["FDA-2013-D-0576-0034", "FDA", "FDA-2013-D-0576", "Reference 14 Target Product Profile_A Strategic Development Process Tool re Considerations for the Design of Early-Phase Clinical Trials of Cellular and Gene Therapy Products; Guidance for Industry", "Supporting & Related Material", "Background Material", "2015-06-11T04:00:00Z", 2015, 6, null, null, "2015-06-11T14:27:16Z", null, 0, 0, "0900006481b2c9e1"], ["FDA-2013-D-0576-0027", "FDA", "FDA-2013-D-0576", "Reference 7 Stem Cell-Derived Cardiomyocytes Demonstrate Arrhythmic Potential, Circulation re Considerations for the Design of Early-Phase Clinical Trials of Cellular and Gene Therapy Products; Guidance for Industry", "Supporting & Related Material", "Background Material", "2015-06-11T04:00:00Z", 2015, 6, null, null, "2015-06-11T14:26:12Z", null, 0, 0, "0900006481b2cdcb"], ["FDA-2013-D-0576-0022", "FDA", "FDA-2013-D-0576", "Reference 2 Content and Review of Chemistry, Manufacturing, and Control (CMC) Information for Human Gene Therapy Investigational New Drug Applications re Considerations for the Design of Early-Phase Clinical Trials of Cellular and Gene Therapy Products; Guidance for Industry", "Supporting & Related Material", "Background Material", "2015-06-11T04:00:00Z", 2015, 6, null, null, "2015-06-11T14:25:22Z", null, 0, 0, "0900006481b2cdce"], ["FDA-2013-D-0576-0023", "FDA", "FDA-2013-D-0576", "Reference 3 Preclinical Assessment of Investigational Cellular and Gene Therapy Products re Considerations for the Design of Early-Phase Clinical Trials of Cellular and Gene Therapy Products; Guidance for Industry", "Supporting & Related Material", "Background Material", "2015-06-11T04:00:00Z", 2015, 6, null, null, "2015-06-11T14:25:28Z", null, 0, 0, "0900006481b2c9db"], ["FDA-2013-D-0576-0028", "FDA", "FDA-2013-D-0576", "Reference 8 Molecular Imaging of Stem Cells Tracking Survival BiodistributionTumorigenicity and Immunogenicity re Considerations for the Design of Early-Phase Clinical Trials of Cellular and Gene Therapy Products; Guidance for Industry", "Supporting & Related Material", "Background Material", "2015-06-11T04:00:00Z", 2015, 6, null, null, "2015-06-11T14:26:18Z", null, 0, 0, "0900006481b2cdcc"], ["FDA-2013-D-0576-0021", "FDA", "FDA-2013-D-0576", "Reference 1 Content and Review of Chemistry, Manufacturing, and Control (CMC) Information for Human Somatic Cell Therapy Investigational New Drug Applications re Considerations for the Design of Early-Phase Clinical Trials of Cellular and Gene Therapy Products; Guidance for Industry", "Supporting & Related Material", "Background Material", "2015-06-11T04:00:00Z", 2015, 6, null, null, "2015-06-11T14:25:16Z", null, 0, 0, "0900006481b2cdcd"], ["FDA-2013-D-0576-0020", "FDA", "FDA-2013-D-0576", "Reference List re Considerations for the Design of Early-Phase Clinical Trials of Cellular and Gene Therapy Products; Guidance for Industry", "Supporting & Related Material", "Background Material", "2015-06-11T04:00:00Z", 2015, 6, null, null, "2015-06-11T14:19:43Z", null, 0, 0, "0900006481b2cdc6"], ["FDA-2013-D-0576-0031", "FDA", "FDA-2013-D-0576", "Reference 11 Gene Therapy Clinical Trials \u2013 Observing Subjects for Delayed Adverse Events re Considerations for the Design of Early-Phase Clinical Trials of Cellular and Gene Therapy Products; Guidance for Industry", "Supporting & Related Material", "Background Material", "2015-06-11T04:00:00Z", 2015, 6, null, null, "2015-06-11T14:27:00Z", null, 0, 0, "0900006481b2c9de"], ["FDA-2013-D-0576-0033", "FDA", "FDA-2013-D-0576", "Reference 13 Content and Format of Investigational New Drug Applications (INDs) for Phase 1 Studies of Drugs, Including Well_Characterized, Therapeutic, Biotechnolgy_derived Products re Considerations for the Design of Early-Phase Clinical Trials of Cellular and Gene Therapy Products; Guidance for Industry", "Supporting & Related Material", "Background Material", "2015-06-11T04:00:00Z", 2015, 6, null, null, "2015-06-11T14:27:11Z", null, 0, 0, "0900006481b2c9e0"], ["FDA-2013-D-0576-0029", "FDA", "FDA-2013-D-0576", "Reference 9 E11 Clinical Investigation of Medicinal Products in the Pediatric Population re Considerations for the Design of Early-Phase Clinical Trials of Cellular and Gene Therapy Products; Guidance for Industry", "Supporting & Related Material", "Background Material", "2015-06-11T04:00:00Z", 2015, 6, null, null, "2015-06-11T14:26:50Z", null, 0, 0, "0900006481b2c9dc"], ["FDA-2013-D-0576-0025", "FDA", "FDA-2013-D-0576", "Reference 5  LMO2-Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1 re Considerations for the Design of Early-Phase Clinical Trials of Cellular and Gene Therapy Products; Guidance for Industry", "Supporting & Related Material", "Background Material", "2015-06-11T04:00:00Z", 2015, 6, null, null, "2015-06-11T14:25:44Z", null, 0, 0, "0900006481b2cdc9"], ["FDA-2013-D-0576-0024", "FDA", "FDA-2013-D-0576", "Reference  4 Fatal systemic inflammatory response syndrome re Considerations for the Design of Early-Phase Clinical Trials of Cellular and\nGene Therapy Products; Guidance for Industry", "Supporting & Related Material", "Background Material", "2015-06-11T04:00:00Z", 2015, 6, null, null, "2015-06-11T14:25:38Z", null, 0, 0, "0900006481b2cdc8"], ["FDA-2013-D-0576-0018", "FDA", "FDA-2013-D-0576", "Considerations for the Design of Early-Phase Clinical Trials of Cellular and\nGene Therapy Products; Guidance for Industry; Availability", "Notice", "Notice of Availability", "2015-06-11T04:00:00Z", 2015, 6, "2015-06-11T04:00:00Z", null, "2015-06-11T13:36:30Z", "2015-14261", 0, 0, "0900006481b2c674"], ["FDA-2013-D-0576-0032", "FDA", "FDA-2013-D-0576", "Reference 12 Formal Meetings Between the FDA and Sponsors or Applicants re Considerations for the Design of Early-Phase Clinical Trials of Cellular and Gene Therapy Products; Guidance for Industry", "Supporting & Related Material", "Background Material", "2015-06-11T04:00:00Z", 2015, 6, null, null, "2015-06-11T14:27:06Z", null, 0, 0, "0900006481b2c9df"], ["FDA-2013-D-0576-0003", "FDA", "FDA-2013-D-0576", "Draft Guidance for Industry:  Considerations for the Design of Early-Phase Clinical Trials of Cellular and Gene Therapy Products; Extension of Comment Period", "Notice", "Notice of Availability", "2013-11-20T05:00:00Z", 2013, 11, "2013-11-20T05:00:00Z", "2014-05-10T03:59:59Z", "2014-05-13T14:34:04Z", "2013-27769", 0, 0, "090000648148ba3d"], ["FDA-2013-D-0576-0001", "FDA", "FDA-2013-D-0576", "Draft Guidance for Industry:  Considerations for the Design of Early-Phase Clinical Trials of Cellular and Gene Therapy Products; Availability", "Notice", "Notice of Availability", "2013-07-02T04:00:00Z", 2013, 7, "2013-07-02T04:00:00Z", "2013-11-23T04:59:59Z", "2014-01-31T02:02:34Z", "2013-15797", 0, 0, "09000064813517c4"], ["FDA-2013-D-0576-0002", "FDA", "FDA-2013-D-0576", "Draft Guidance for Industry:  Considerations for the Design of Early-Phase Clinical Trials of Cellular and Gene Therapy Products", "Other", "Guidance", "2013-07-02T04:00:00Z", 2013, 7, "2013-07-02T04:00:00Z", null, "2024-11-12T05:16:03Z", null, 1, 0, "0900006481350f90"]], "truncated": false, "filtered_table_rows_count": 20, "expanded_columns": [], "expandable_columns": [[{"column": "docket_id", "other_table": "dockets", "other_column": "id"}, "title"]], "columns": ["id", "agency_id", "docket_id", "title", "document_type", "subtype", "posted_date", "posted_year", "posted_month", "comment_start_date", "comment_end_date", "last_modified", "fr_doc_num", "open_for_comment", "withdrawn", "object_id"], "primary_keys": ["id"], "units": {}, "query": {"sql": "select id, agency_id, docket_id, title, document_type, subtype, posted_date, posted_year, posted_month, comment_start_date, comment_end_date, last_modified, fr_doc_num, open_for_comment, withdrawn, object_id from documents where \"docket_id\" = :p0 order by posted_date desc limit 101", "params": {"p0": "FDA-2013-D-0576"}}, "facet_results": {"agency_id": {"name": "agency_id", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?docket_id=FDA-2013-D-0576", "results": [{"value": "FDA", "label": "FDA", "count": 20, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2013-D-0576&agency_id=FDA", "selected": false}], "truncated": false}, "document_type": {"name": "document_type", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?docket_id=FDA-2013-D-0576", "results": [{"value": "Supporting & Related Material", "label": "Supporting & Related Material", "count": 15, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2013-D-0576&document_type=Supporting+%26+Related+Material", "selected": false}, {"value": "Notice", "label": "Notice", "count": 3, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2013-D-0576&document_type=Notice", "selected": false}, {"value": "Other", "label": "Other", "count": 2, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2013-D-0576&document_type=Other", "selected": false}], "truncated": false}, "posted_year": {"name": "posted_year", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?docket_id=FDA-2013-D-0576", "results": [{"value": 2015, "label": 2015, "count": 17, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2013-D-0576&posted_year=2015", "selected": false}, {"value": 2013, "label": 2013, "count": 3, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2013-D-0576&posted_year=2013", "selected": false}], "truncated": false}}, "suggested_facets": [{"name": "subtype", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2013-D-0576&_facet=subtype"}, {"name": "posted_date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2013-D-0576&_facet=posted_date"}, {"name": "posted_month", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2013-D-0576&_facet=posted_month"}, {"name": "comment_start_date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2013-D-0576&_facet=comment_start_date"}, {"name": "open_for_comment", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2013-D-0576&_facet=open_for_comment"}, {"name": "posted_date", "type": "date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2013-D-0576&_facet_date=posted_date"}, {"name": "comment_start_date", "type": "date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2013-D-0576&_facet_date=comment_start_date"}, {"name": "comment_end_date", "type": "date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2013-D-0576&_facet_date=comment_end_date"}, {"name": "last_modified", "type": "date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2013-D-0576&_facet_date=last_modified"}], "next": null, "next_url": null, "private": false, "allow_execute_sql": true, "query_ms": 12.69429293461144, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}